Health Tech Nurx Completes C Series Funding
Health tech firm Nurx has completed their C series funding round, raising US$52million. The US based company provides sexual and reproductive health care to over 200,000 patients across the country.
The funding was led by Kleiner Perkins Digitial Growth Fund and Union Square Ventures. The new funding is going to be used to expand services, with at-home testing for sexually transmitted infections (STIs) on top of the list.
Nurx has seen rapid growth, with month on month patient growth standing at 20%, with 40% of all clients coming from southern states, where access to reproductive health is notoriously difficult. Around 20million American women live in contraception deserts according to Power to Decide, a issue Nurx is working to fix.
An app is all a client needs to be able to get access to contraception and screening, eliminating access barriers many women face. The system also allows access to cutting edge HIV treatments, PrEP can be discussed and delivered without physically seeing a clinician and the service helps find coverage or funding for those in need.
"The Nurx platform has allowed the company to connect hundreds of thousands of people with
its medical team by tackling many of the common barriers people face when trying to access
healthcare," said Andy Weissman, Managing Partner at Union Square Ventures. "Our
investment in the Series C round mirrors our conviction in the Nurx team to make an even larger
impact on public health needs."